Artivion, Inc. (NYSE:AORT) Shares Bought by BNP Paribas Financial Markets

BNP Paribas Financial Markets raised its position in shares of Artivion, Inc. (NYSE:AORT) by 9.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 31,298 shares of the company’s stock after acquiring an additional 2,724 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.07% of Artivion worth $895,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the company. Barclays PLC boosted its stake in shares of Artivion by 346.3% in the third quarter. Barclays PLC now owns 70,877 shares of the company’s stock worth $1,888,000 after acquiring an additional 54,996 shares during the last quarter. Calamos Advisors LLC lifted its holdings in Artivion by 113.7% in the 4th quarter. Calamos Advisors LLC now owns 63,029 shares of the company’s stock valued at $1,802,000 after purchasing an additional 33,541 shares in the last quarter. Franklin Resources Inc. boosted its stake in Artivion by 14.4% during the 3rd quarter. Franklin Resources Inc. now owns 21,107 shares of the company’s stock worth $553,000 after purchasing an additional 2,663 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in Artivion during the 4th quarter worth $194,000. Finally, New York State Common Retirement Fund grew its holdings in shares of Artivion by 2.5% during the fourth quarter. New York State Common Retirement Fund now owns 41,017 shares of the company’s stock worth $1,173,000 after buying an additional 1,000 shares in the last quarter. Institutional investors and hedge funds own 86.37% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on AORT. Needham & Company LLC reissued a “buy” rating and issued a $32.00 price target on shares of Artivion in a research note on Tuesday, May 6th. Citizens Jmp upgraded shares of Artivion to a “strong-buy” rating in a report on Tuesday, May 6th. Stifel Nicolaus decreased their target price on shares of Artivion from $33.00 to $30.00 and set a “buy” rating on the stock in a research note on Tuesday, February 25th. Finally, JMP Securities restated a “market outperform” rating and issued a $33.00 price target on shares of Artivion in a research report on Tuesday, May 6th. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Artivion presently has a consensus rating of “Buy” and an average target price of $31.40.

Artivion Trading Down 2.1%

Shares of AORT stock opened at $28.55 on Thursday. The company has a current ratio of 1.88, a quick ratio of 1.33 and a debt-to-equity ratio of 0.71. The company’s 50-day moving average price is $24.96 and its 200-day moving average price is $27.35. Artivion, Inc. has a twelve month low of $21.97 and a twelve month high of $32.33. The stock has a market cap of $1.22 billion, a price-to-earnings ratio of -1,427.25 and a beta of 1.54.

Artivion (NYSE:AORT) last released its quarterly earnings data on Monday, May 5th. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.06). The business had revenue of $98.98 million during the quarter, compared to analyst estimates of $94.81 million. Artivion had a negative net margin of 0.22% and a positive return on equity of 5.15%. As a group, equities analysts predict that Artivion, Inc. will post 0.37 earnings per share for the current year.

Insider Activity

In other news, CEO James P. Mackin sold 42,156 shares of the company’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $27.31, for a total value of $1,151,280.36. Following the transaction, the chief executive officer now directly owns 663,882 shares in the company, valued at approximately $18,130,617.42. This represents a 5.97% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Jean F. Holloway sold 5,335 shares of the stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $27.31, for a total transaction of $145,698.85. Following the transaction, the senior vice president now directly owns 149,799 shares of the company’s stock, valued at $4,091,010.69. The trade was a 3.44% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 111,273 shares of company stock valued at $2,951,340 in the last quarter. Insiders own 7.60% of the company’s stock.

Artivion Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.